US-based clinical-stage biotechnology company Vyriad will collaborate with Imanis Life Sciences to develop in-vitro and in-vivo theranostic tests to predict a cancer patient’s responsiveness to Vyriad’s oncolytic virus therapeutics.

Under the agreement, Imanis will use its patented virus technology to develop and preclinically attest a companion diagnostic test which will be designed to predict cancer patient’s clinical response to oncolytic virotherapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Vyriad will select one or two test formats in its clinical trials to further evaluate the predictive power of the tests.

"For the first time, we will be able to focus our efforts on those patients with a higher probability of deriving clinical benefit from our drugs while avoiding treating patients that are not likely to respond to them."

It is planning to pursue clinical validation and regulatory approval for the tests to be applied in human and animal.

After being approved, Imanis will grant Vyriad a nonexclusive license to use the companion diagnostic tests for the development of its patented oncolytic viruses derived from the company’s vesicular stomatitis virus (VSV), measles virus, or other Vyriad platforms.

See Also:

Vyriad CEO Stephen Russell said: “We are excited to initiate this collaboration with Imanis Life Sciences for the development of theranostic tests that will help us to streamline patient selection and maximise response rates in Vyriad-sponsored oncolytic virotherapy clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“For the first time, we will be able to focus our efforts on those patients with a higher probability of deriving clinical benefit from our drugs while avoiding treating patients that are not likely to respond to them.

“We strongly expect that pairing our oncolytic virotherapies with theranostic tests being developed in this collaboration will greatly accelerate the pathway to FDA marketing approval for our oncolytic virotherapy products.”

Vyriad’s theranostic tests use recombinant vesicular stomatitis viruses to release theranostically informative reporter genes and are permitted to be used as diagnostic reagents in the hospital.